Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
about
The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
P2860
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@en
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@nl
type
label
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@en
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@nl
prefLabel
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@en
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@nl
P2093
P2860
P1476
Mirabegron for the treatment o ...... dicare Advantage perspectives.
@en
P2093
Daniel B Ng
Linda M Posta
Noll L Campbell
Robert W Klein
Ronald C Wielage
Sinem Perk
Thomas Yuran
Timothy M Klein
P2860
P304
P356
10.1080/13696998.2016.1204307
P407
P577
2016-06-21T00:00:00Z